COMPARISON OF EARLY TREATMENT- EMERGENT COMPLICATIONS OF STAGE III A NON-SMALL CELL CARCINOMA (NSCLC STAGE III A) IN PATIENTS TREATED WITH NEOADJUVANT CHEMORADIOTHERAPY (NHLT), (NCHT), AND NEOADJUVANT CHEMOTHERAPY AND ADJUVANT RADIATION THERAPY

K. A. Malyarchuk, A. Ganul, B. O. Borysyuk, L. Bororov, A. Shevchenko, V. Sovenko
{"title":"COMPARISON OF EARLY TREATMENT- EMERGENT COMPLICATIONS OF STAGE III A NON-SMALL CELL CARCINOMA (NSCLC STAGE III A) IN PATIENTS TREATED WITH NEOADJUVANT CHEMORADIOTHERAPY (NHLT), (NCHT), AND NEOADJUVANT CHEMOTHERAPY AND ADJUVANT RADIATION THERAPY","authors":"K. A. Malyarchuk, A. Ganul, B. O. Borysyuk, L. Bororov, A. Shevchenko, V. Sovenko","doi":"10.31612/2616-4868.1(23).2023.04","DOIUrl":null,"url":null,"abstract":"Treatment of STAGE III A NSCLC is an extremely difficult problem for modern oncology, since the one-year survival rate from the moment of diagnosis according to the National Cancer Registry is up to 58%. At the same time, there is a situation of uncertainty in the clinical approach to the treatment of this pathology – neither NCCN nor other world scientific literature sources contain information regarding a specific treatment method. The advantage of none of the possible methods of treatment of stage III NSCLC (HCT, NHLT, HCT + adjuvant PT) is not proven in relation to others. The conducted study is devoted to comparing these methods in relation to each other and overall and relapse-free survival. According to the results of previous studies, the highest results of both general and relapse-free survival were shown by patients from the NHLT group. But an important aspect of treatment is the ratio of benefit and risk, that is, the number and severity of complications. The study and analysis of complications of treatment with the methods of NXT, NHLT and NXT + adjuvant PT was the task of the work. Goal. To investigate and determine the number of complications in groups with NCRT, NCT and NCT + adjuvant LT. Materials and methods. The study included 3 groups of patients – patients who received NHLT, NHT and NHT + adjuvant PT, a total of 304 people. All patients had the same chemotherapy regimen- Cisplatin / Docetaxel or Carboplatin / Paclitaxel, patients receiving radiation therapy received it in a total dosage of 30 Gy in both neoadjuvant and adjuvant regimens. The irradiation was carried out on the chest and mediastinum area. Patients underwent radical surgery in the form of lobectomy, bilobectomy or pneumonectomy. In early works on this topic, an analysis of survival on the Kaplan and Mayer scale was carried out. The article describes the conduct and study of treatment complications that were recorded during the stay of patients in the hospital both during chemotherapy, radiation therapy and in the postoperative period.","PeriodicalId":34164,"journal":{"name":"Klinichna ta profilaktichna meditsina","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Klinichna ta profilaktichna meditsina","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31612/2616-4868.1(23).2023.04","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Treatment of STAGE III A NSCLC is an extremely difficult problem for modern oncology, since the one-year survival rate from the moment of diagnosis according to the National Cancer Registry is up to 58%. At the same time, there is a situation of uncertainty in the clinical approach to the treatment of this pathology – neither NCCN nor other world scientific literature sources contain information regarding a specific treatment method. The advantage of none of the possible methods of treatment of stage III NSCLC (HCT, NHLT, HCT + adjuvant PT) is not proven in relation to others. The conducted study is devoted to comparing these methods in relation to each other and overall and relapse-free survival. According to the results of previous studies, the highest results of both general and relapse-free survival were shown by patients from the NHLT group. But an important aspect of treatment is the ratio of benefit and risk, that is, the number and severity of complications. The study and analysis of complications of treatment with the methods of NXT, NHLT and NXT + adjuvant PT was the task of the work. Goal. To investigate and determine the number of complications in groups with NCRT, NCT and NCT + adjuvant LT. Materials and methods. The study included 3 groups of patients – patients who received NHLT, NHT and NHT + adjuvant PT, a total of 304 people. All patients had the same chemotherapy regimen- Cisplatin / Docetaxel or Carboplatin / Paclitaxel, patients receiving radiation therapy received it in a total dosage of 30 Gy in both neoadjuvant and adjuvant regimens. The irradiation was carried out on the chest and mediastinum area. Patients underwent radical surgery in the form of lobectomy, bilobectomy or pneumonectomy. In early works on this topic, an analysis of survival on the Kaplan and Mayer scale was carried out. The article describes the conduct and study of treatment complications that were recorded during the stay of patients in the hospital both during chemotherapy, radiation therapy and in the postoperative period.
新辅助放化疗(NHLT)、新辅助化疗(NCHT)与新辅助化疗和辅助放射治疗患者III期A非小细胞癌(NSCLC III期A)早期治疗并发症的比较
III期A NSCLC的治疗对于现代肿瘤学来说是一个极其困难的问题,因为根据国家癌症登记处的数据,从诊断开始的一年生存率高达58%。与此同时,这种病理学的临床治疗方法存在不确定性——NCCN和其他世界科学文献来源都不包含有关特定治疗方法的信息。没有一种可能的III期NSCLC治疗方法(HCT、NHLT、HCT+辅助PT)的优势与其他方法相比得到证实。所进行的研究致力于比较这些方法之间的相互关系以及总体和无复发生存率。根据先前的研究结果,NHLT组的患者在一般生存率和无复发生存率方面的结果最高。但治疗的一个重要方面是获益与风险的比例,即并发症的数量和严重程度。研究和分析NXT、NHLT和NXT+辅助PT治疗的并发症是本工作的任务。球门研究和确定NCRT、NCT和NCT+佐剂LT组的并发症数量。材料和方法。该研究包括3组患者——接受NHLT、NHT和NHT+辅助PT的患者,共304人。所有患者均采用相同的化疗方案-顺铂/多西他赛或卡铂/紫杉醇,接受放射治疗的患者在新辅助和辅助方案中均接受总剂量为30 Gy的化疗。照射部位为胸部和纵隔。患者接受了肺叶切除术、双叶切除术或全肺切除术等根治性手术。在关于这个主题的早期工作中,对Kaplan和Mayer量表的生存进行了分析。本文描述了患者在化疗、放疗和术后住院期间记录的治疗并发症的处理和研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.10
自引率
0.00%
发文量
34
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信